Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel–Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study

Genetics in Medicine, Published online: 12 August 2021; doi:10.1038/s41436-021-01290-ySafety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel–Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study

Source: Genetics in Medicine - August 12, 2021 Category: Genetics & Stem Cells Authors: M. Luu P. Vabres H. Devilliers R. Loffroy A. Phan L. Martin F. Morice-Picard F. Petit M. Willems D. Bessis M. L. Jacquemont A. Maruani C. Chiaverini T. Mirault J. Clayton-Smith M. Carpentier C. Fleck A. Maurer M. Yousfi V. E. R. Parker R. K. Semple M. Bar Source Type: research